The order eases restrictions on psychedelic drugs like ibogaine to spur research on using them for medical purposes.

By Kamal Choudhury and Christy Santhosh May 18 (Reuters) - U.S. President Donald Trump's executive order to accelerate ...

The US president said his directive will help "dramatically accelerate" access to research and treatments on psychedelic ...

President Donald Trump has signed an executive order aimed at speeding up research and access to psychedelic drugs as potential treatments for serious mental health conditions. The move directs ...

Executive order to speed access to psychedelic treatments likely to have limited legal impact despite high-profile push ...

Like this article? Keep independent journalism alive. Support HuffPost. The Food and Drug Administration has announced efforts to expedite its research into perception-altering psychedelic medications ...

The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the ...

The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest ...

The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help treat post-traumatic stress disorder.